

The Manager  
Company Announcements Office  
ASX Limited

## FIRST ROYALTY PAYMENT RECEIVED

**Adelaide, 6 October 2009:** LabTech Systems Ltd (ASX: LBT) announces that it has received the first royalty payment of AU\$111,350 under its agreement with bioMérieux. This is part payment of the minimum royalty provision for the calendar year 2009.

*“This first payment of royalties to LabTech Systems for MicroStreak® applicators used in the PREVI™ Isola instruments sold by bioMérieux is a major milestone in the company’s history. Significant revenues may be generated by these ongoing royalties as the use of the patented disposable applicators grows in clinical laboratories throughout the world over the next few years”,* said Chairman, Bob Finder.

PREVI™ Isola was launched into the global marketplace in December last year. In the current fiscal year commencing July 2009, LabTech Systems is just beginning to receive income from royalties for the disposable MicroStreak® applicators that are used during the operation of the instrument.

The partnering agreement with bioMérieux provides for a double-digit percentage royalty rate to be paid on sales of applicators. The quantum of this royalty is commercial-in-confidence.

In addition to further payments of royalties arising from the MicroStreak® applicators, a significant milestone payment of approximately AU\$3.4million is expected from bioMérieux in April 2010.

The company has previously received AU\$6.67million in milestone payments from bioMérieux for the development and manufacturing establishment of the PREVI™ Isola automated microbiology agar plate streaker that incorporates the breakthrough MicroStreak® applicator.

bioMérieux now has ongoing responsibility for the manufacture, marketing and distribution of PREVI™ Isola. There are no further obligations upon LabTech Systems in relation to costs for any further development of the core technology, nor for providing working capital for manufacture and distribution, nor for marketing costs.

--ENDS--

### About LabTech Systems

LabTech Systems is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company was formed in 2004 and listed on the Australian Securities Exchange on 31 July 2006 (ASX: LBT). The focus of the company has been the commercialisation of its first product, known as MicroStreak®.

In 2007, LabTech Systems signed an agreement with French diagnostics giant bioMérieux to commercialise and market this invention, which is now known as PREVI™ Isola. This instrumentation product comprises a central part of bioMérieux’s FMLA™ (Full Microbiology Lab Automation™) strategy.

Going forward, LabTech Systems intends to continue its track record of innovation in microbiology, while also fully exploiting its existing commercial relationships and intellectual property portfolio.

For more information, see [www.labtechsystems.com](http://www.labtechsystems.com).

**About bioMérieux**

**“Advancing Diagnostics to Improve Public Health”** A world leader in the field of *in vitro* diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2008, revenues reached €1.111 billion with 84% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at [www.biomerieux.com](http://www.biomerieux.com)

**CONTACTS**

LabTech Systems	Media Relations
<b>Lusia Guthrie</b> CEO & MD Tel: +61 (0)8 8227 1555 E: <a href="mailto:info@labtechsystems.com">info@labtechsystems.com</a>	<b>Emma Power / Rudi Michaelson</b> Monsoon Communications Tel: +61 (0)3 9620 3333 E: <a href="mailto:emmap@monsoon.com.au">emmap@monsoon.com.au</a>